DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

Авторы

  • Azizbek Izatillayev Shifokor-endokrinolog Namangan shahri “Doktor-A” klinikasi Автор

Ключевые слова:

type 2 diabetes mellitus

Аннотация

Sarcopenia and type 2 diabetes mellitus (T2DM) share common pathophysiological mechanisms and are mutually aggravating, which makes the search for pathogenetically justified treatment approaches an urgent task. The present study examined changes in myokine status and metabolic parameters in patients with T2DM and sarcopenia receiving comprehensive therapy. A total of 55 patients aged 55 to 65 years were examined: 35 patients with T2DM and sarcopenia (Group 1) and 20 patients with T2DM without sarcopenia (Group 2). Sarcopenia was diagnosed according to the EWGSOP criteria using handgrip dynamometry, dual-energy X-ray absorptiometry, and a gait speed test. Comprehensive therapy comprised optimized glucose-lowering treatment, loading doses of vitamin D, a high-protein diet, and an individualized program of aerobic and resistance training. After six months, both groups achieved comparable improvement in carbohydrate metabolism, whereas the reduction in insulin resistance was more pronounced in Group 1 (HOMA-IR decreased 1.74-fold versus 1.41-fold in Group 2). In patients with sarcopenia, serum myostatin decreased by 33.6%, irisin increased 1.67-fold, and vitamin D reached optimal values. These changes were accompanied by significant gains in handgrip strength, skeletal muscle index, and gait speed. Before treatment, myostatin correlated positively with insulin resistance and inversely with muscle strength, vitamin D level, and gait speed; after treatment these associations weakened. The findings demonstrate the reversibility of sarcopenic processes when pathogenetic treatment is started in a timely manner. However, muscle function indicators in Group 1 remained lower than in patients without sarcopenia, indicating the need for prolonged rehabilitation and long-term monitoring of myokine status.

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Библиографические ссылки

1. Marcotte-Chénard A, Oliveira B, Little JP, Candow DG. Sarcopenia and type 2 diabetes: pathophysiology and potential therapeutic lifestyle interventions. Diabetes Metab Syndr. 2023;17:102835.

2. Kim S, Kim S, Hong KH. Association of combining diet and physical activity on sarcopenia and obesity in elderly Koreans with diabetes. Nutrients. 2024;16:964.

3. Lo JH, et al. Sarcopenia: current treatments and new regenerative therapeutic approaches. J Orthop Translat. 2020;23:38–52.

4. Johri N, et al. A comprehensive review on the risks assessment and treatment options for sarcopenia in people with diabetes. J Diabetes Metab Disord. 2023;22(2):995–1010.

5. Witham MD, Granic A, Pearson E, Robinson SM, Sayer AA. Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia – a narrative review. Drugs Aging. 2023;40(8):703–719. doi:10.1007/s40266-023-01042-4

6. Qaisar R, Karim A, Muhammad T, Iqbal MS, Ahmad F. Metformin improves sarcopenia-related quality of life in geriatric adults: a randomized controlled trial. Arch Med Res. 2024;55:102998.

7. Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22:79.

8. Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opin Pharmacother. 2019;20:1645–1657.

9. Bhasin S, Krishnan V, Storer TW, Steiner M, Dobs AS. Androgens and selective androgen receptor modulators to treat functional limitations associated with aging and chronic disease. J Gerontol A Biol Sci Med Sci. 2023;78:25–31.

10. He Q, Wang X, Yang C, Zhuang X, Yue Y, Jing H, et al. Metabolic and nutritional characteristics in middle-aged and elderly sarcopenia patients with type 2 diabetes. J Diabetes Res. 2020;2020:6973469.

11. Нишанова МС, Айсачева МО, Захиров АС. ГИПОВИТАМИНОЗ ВИТАМИНА D 3 КАК ПРЕДИКТОР УХУДШЕНИЯ ГЛИКЕМИЧЕСКОГО КОНТРОЛЯ У ЖЕНЩИН С ПРЕДИАБЕТОМ. Медицинский журнал молодых ученых. 2025(14 (06)):297-300.

Опубликован

2026-10-12